Company Overview

Company name: True Leaf Medicine International (CNQ: MJ)
Description: Producer of federally-approved medicinal cannabis products intended to improve the quality of life for people and their pets with natural alternatives. The company provides licensed plant and hemp-seed based pet healthcare products for the Canadian market.
Year founded: 2013
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
City: Vernon
State: British Columbia
Country: Canada
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 3.26
Business status: Profitable
Ownership: Publicly Held
Exchange: CNQ
Ticker: MJ
Revenue (USD Million): 1.25
Gross profit (USD Million): 0.57
Net income (USD Million) -2.64
Enterprise value: 38.92
Earnings before interest, tax, depreciation and amortization (EBITDA): -2.57
Fiscal period: TTM 1Q2019
Financing Status: The company (CSE: MJ) received CAD 4.051 million of developmental capital from an undisclosed investor on January 24, 2018 through a private placement. The company also raised CAD 10 million through a Regulation A+ public equity offering, two months after the U.S. Securities and Exchange Commission (SEC) qualified its offering statement. In the Regulation A+ offering, True Leaf offered a total of 14,285,715 common shares at a price of CAD 0.70 per share, with a minimum subscription amount of CAD 350 (or 500 shares) per investor.
Number of active investors:
Profile last updated: 27-Nov-2018
Last known valuation:
Last known valuation date: